Genmab A/SGMAB
Key ratios
Operating cash flow growth
-14.1%TTM
2025
5.3%2024
5.1%2023
84.9%
EPS growth
-36.8%TTM
2025
-12.3%2024
83.0%2023
-21.7%
FCF / Sales
21.0%TTM
2025
30.9%2024
35.2%2023
42.6%
Net margin
19.1%TTM
2025
25.9%2024
36.3%2023
26.4%
ROA
8.1%2025
2024
10.9%2023
10.0%
ROE
17.5%2025
2024
23.1%2023
14.5%
Revenue growth
22.3%TTM
2025
19.2%2024
30.6%2023
11.3%
Recent news
Genmab to Participate in Upcoming Investor Conferences
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Track GMAB in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer